

# New and Imminent Therapies for AD: Impact on the ADRD Research Landscape

Suzanne Craft, PhD

Director

Wake Forest University School of Medicine ADRC



# Disclosures

---

- S.C. is a Scientific Advisory Board member for T3D Therapeutics
- Content will include reference to commercial products; however, generic and alternative products will be discussed whenever possible
- Investigational products and their ongoing trials will be discussed



# The framework:

- Two new therapies for AD were FDA-approved in the past year
- Results of Clarity AD trial promising, though many questions remain
  - Diversity
  - Responder characteristics
  - Safety
  - Cost and access
- Today's panel will not focus on strengths or limitations of newly approved treatments, but implications for current and future AD research




# Wave theory of scientific progress

- Advent of initial disease-modifying therapies often precedes proliferation of new treatments
- Example: Cancer




# Wave theory of scientific progress: Lessons from HIV


1969



# Wave theory of scientific progress: Lessons from HIV




Trends in Annual Age-Adjusted\* Rates of Death with HIV Infection as the Underlying Cause, 1987–2018—United States



# Will AD therapeutics mirror this pattern?

Publications related to AD  
therapeutics since 1965


PER 100,000 PUBMED CITATIONS




MADE WITH GITHUB.IO/PUBMED-BY-YEAR

# Will AD therapeutics mirror this pattern?

31 agents currently in Phase 3 trials






Cummings et al., TRCI, 2022





# Will AD therapeutics mirror this pattern?

152 NIH-funded non-pharmacologic trials in progress



# Charge for the Panel

---

- Discuss the anticipated impact of impending disease modifying treatments for AD on ongoing trials and observational studies
- Describe strategies planned to address impact
- Discuss issues to be considered for planning future studies
- Provide innovative ideas for a positive path forward during this time of opportunity

# Our Panel



**Reisa Sperling, MD**



**Walter 'Bud' Kukull, PhD**



**Liana Apostolova,  
MD, MSc, FAAN**

**Ron Petersen, MD,  
PhD**



**Randall Bateman, MD**